Candel Therapeutics
CADL
23 hedge funds and large institutions have $34M invested in Candel Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
15% more funds holding
Funds holding: 20 → 23 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.97% less ownership
Funds ownership: 24.23% → 23.26% (-0.97%)
38% less capital invested
Capital invested by funds: $54.4M → $34M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$372K |
| 2 |
BlackRock
New York
|
+$87.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.1K |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$62.1K |
| 5 |
EAM
Empirical Asset Management
Wellesley,
Massachusetts
|
+$59.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.44M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$782K |
| 3 |
Millennium Management
New York
|
-$102K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.2K |
CADL Hedge Fund Activity: Q1 2022 in Review
23 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q1 2022, worth a combined $34M — down 38% from $54.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CADL positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $372K. The largest seller was Fidelity Investments, cutting an estimated $1.44M.
- 23 institutional investors held Candel Therapeutics (CADL) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $34M of Candel Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
- 5 funds opened new Candel Therapeutics positions in Q1 2022 and 2 closed out, a net change of +3 holders.
- The largest Candel Therapeutics buyer in Q1 2022 was Bridgeway Capital Management, an estimated $372K added.
- The largest Candel Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $1.44M sold.
Based on aggregated 13F filings for Q1 2022.